News

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound.

“Dr. Kassell’s visionary leadership and enduring contributions to the field have been truly transformative,” said ISTU President Elisa Konofagou, PhD, who is also the Robert and Margaret Hariri Professor of Biomedical Engineering at Columbia University. “He has devoted the past two decades to transforming the lives of patients through ensuring continuous funding for focused ultrasound, championing innovation and collaboration, and accelerating the path from scientific discovery to patient care.”

A renowned neurosurgeon, Dr. Kassell established the Focused Ultrasound Foundation in 2006 to help raise awareness and accelerate adoption of focused ultrasound. Since then, both the body of research and the global community of scientists and clinicians have dramatically expanded, increasing the range of treatable conditions and bringing focused ultrasound closer to becoming a standard of care for countless patients worldwide. Globally, more than one million patients have been treated, and focused ultrasound is being researched to treat more than 180 diseases. In the past two decades, the Foundation has become the largest non-governmental funding source for focused ultrasound research. This November, as the organization celebrates its 20th anniversary, we will celebrate the milestone and the technology’s immense progress at an event in McLean, Virginia.

“I’m deeply honored to receive this recognition, but I accept it on behalf of the entire Focused Ultrasound Foundation team and the many researchers, clinicians, industry partners, philanthropists, and patients who have worked tirelessly to advance this field,” said Dr. Kassell. “The progress we’ve made has always been a collective effort, and this award reflects what can be achieved when an entire community is united around a common mission.”

Read more here.

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …